<unk> , sold under the brand name Brukinsa, is a medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL).<unk>  is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth. It was approved for medical use in the United States in November 2019.
Zanubrutinib
Acalabrutinib
Tucatinib
Ponatinib
Fostamatinib
Neratinib
Imatinib
Brigatinib